We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Evaluate the Safety of GABITRIL in Adults With Generalized Anxiety Disorder

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00233675
First Posted: October 6, 2005
Last Update Posted: May 9, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Teva Pharmaceutical Industries ( Cephalon )
  Purpose
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).

Condition Intervention Phase
General Anxiety Disorder Drug: GABITRIL (tiagabine hydrochloride; CEP-6671) Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder

Resource links provided by NLM:


Further study details as provided by Teva Pharmaceutical Industries ( Cephalon ):

Study Start Date: August 2003
Primary Completion Date: February 2005 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00233675


  Show 28 Study Locations
Sponsors and Collaborators
Cephalon
Investigators
Study Director: Charles Brown, MD Cephalon
  More Information

Responsible Party: Cephalon
ClinicalTrials.gov Identifier: NCT00233675     History of Changes
Other Study ID Numbers: C6671A/301/AX/US
First Submitted: September 27, 2005
First Posted: October 6, 2005
Last Update Posted: May 9, 2014
Last Verified: May 2014

Additional relevant MeSH terms:
Disease
Anxiety Disorders
Pathologic Processes
Mental Disorders
Tiagabine
Anticonvulsants
Neurotransmitter Uptake Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Physiological Effects of Drugs
GABA Agonists
GABA Agents